<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02747563</url>
  </required_header>
  <id_info>
    <org_study_id>0210-15-KMC</org_study_id>
    <nct_id>NCT02747563</nct_id>
  </id_info>
  <brief_title>Evaluation of PSA Blood Levels Prior to and After Digital Rectal Examination</brief_title>
  <official_title>Evaluation of PSA Blood Levels in Men on Active Surveillance and Men With Benign Prostatic Hyperplasia Prior to and After Digital Rectal Examination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaplan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaplan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with know prostate cancer (PCa) under active surveillance and aged matched controls
      without evidence of PCa will have a PSA blood test prior to and following standardized
      digital rectal examination
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with know prostate cancer (PCa) under active surveillance (Gleason 6, PSA &lt; 10
      ng/ml) and aged matched controls without evidence of PCa will have a PSA blood test prior to
      and following standardized digital rectal examination.

      The change of PSA will be evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of PSA elevation after DRE</measure>
    <time_frame>1 hour</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Active Surveillance</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with known prostate cancer eligible for active surveillance Intervention - PSA measurement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients without known diagnosis of prostate cancer Intervention - PSA measurement</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood test (PSA)</intervention_name>
    <description>Measurement of blood PSA levels</description>
    <arm_group_label>Active Surveillance</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males

          -  Intact Rectum

          -  Prostate Cancer eligible for active surveillance

        Exclusion Criteria:

          -  Pror radiation therapy

          -  Under Androgen Deprivation Therapy

          -  Prior prostate surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Uri Lindner, M.D.</last_name>
    <email>urili@clalit.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Uri Lindner, M.D.</last_name>
      <email>urili@clalit.org.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>April 20, 2016</last_update_submitted>
  <last_update_submitted_qc>April 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaplan Medical Center</investigator_affiliation>
    <investigator_full_name>Dr Uri Lindner</investigator_full_name>
    <investigator_title>Dr. Uri Lindner, Staff Urologist, Kaplan Medical Center</investigator_title>
  </responsible_party>
  <keyword>prostate cancer</keyword>
  <keyword>PSA</keyword>
  <keyword>digital rectal examination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

